We have located links that may give you full text access.
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Feasibility study of zoledronic acid plus cisplatin-docetaxel as first-line treatment for advanced non-small cell lung cancer with bone metastases.
Anticancer Research 2012 September
BACKGROUND: This study evaluated the safety and efficacy of combined zoledronic acid, cisplatin and docetaxel in patients with non-small cell lung cancer (NSCLC) with bone metastases.
PATIENTS AND METHODS: Cisplatin 80 mg/m(2) and docetaxel 60 mg/m(2) with zoledronic acid 4 mg were given intravenously on day 1 every 3-4 weeks. The primary endpoint was feasibility of concomitant administration of zoledronic acid and cisplatin.
RESULTS: Thirty-five chemonaïve patients were enrolled. The median number of treatment cycles was four, and two or more cycles were administered in 29 (83%) patients without severe toxicity. No grade 3 or 4 renal toxicity was observed. The objective response rate was 29% and the 1-year survival rate was 37%. The pain score improved in 77% of the patients after six weeks.
CONCLUSION: The combination of zoledronic acid, cisplatin and docetaxel is well-tolerated with acceptable renal toxicity, and has modest activity as a first-line treatment of NSCLC patients with bone metastases.
PATIENTS AND METHODS: Cisplatin 80 mg/m(2) and docetaxel 60 mg/m(2) with zoledronic acid 4 mg were given intravenously on day 1 every 3-4 weeks. The primary endpoint was feasibility of concomitant administration of zoledronic acid and cisplatin.
RESULTS: Thirty-five chemonaïve patients were enrolled. The median number of treatment cycles was four, and two or more cycles were administered in 29 (83%) patients without severe toxicity. No grade 3 or 4 renal toxicity was observed. The objective response rate was 29% and the 1-year survival rate was 37%. The pain score improved in 77% of the patients after six weeks.
CONCLUSION: The combination of zoledronic acid, cisplatin and docetaxel is well-tolerated with acceptable renal toxicity, and has modest activity as a first-line treatment of NSCLC patients with bone metastases.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app